Neuroacanthocytosis
Table of Contents (click to jump to sections)
What is Neuroacanthocytosis?Is there any treatment?What is the prognosis?What research is being done?OrganizationsWhat is Neuroacanthocytosis?
Neuroacanthocytosis is a rare movement disorder marked by progressive muscle weakness and atrophy, progressive cognitive loss,
chorea (involuntary twisting movements of the body), and acanthocytosis (spiked red blood cells associated with several inherited
neurological disorders). Other symptoms include facial tics, uncontrolled muscle movement, instability when walking, seizures,
biting of the tongue and lips, and changes in personality, comprehension, and judgment. The disorder is due to degeneration
of the basal ganglia (a part of the brain that helps control movement) and loss of neurons in the brain and spinal cord. Neuroacanthocytosis
has adult and childhood varieties. In adults, onset of classic symptoms is usually begins between ages 20 and 50, while in
children onset is typically seen in adolescence (but may occur earlier). Adult varieties can involve the heart and immune
system. Neuroacanthocytosis is typically an inherited autosomal recessive disorder and is more common in males than in females.
Some types of neuroacanthocytosis have been found to be caused by specific gene defects. Parkinsonism has been associated
with the disorder in some patients.
Is there any treatment?
Treatment is symptomatic and supportive. Antipsychotic drugs that block dopamine, such as haloperidol, can provide temporary
relief from tics and chorea. Drugs used to decrease anxiety, such as diazepam and benzodiazepine, can also decrease movement
disorders, which are often made worse by associated stress. Injections of botulinum toxin can relax muscles and reduce unintentional
movement. Other drug therapy may include anticonvulsants and antidepressants. Proper nutrition is required. A feeding tube
may be needed for some patients as the disorder progresses. Speech therapy and physical therapy may provide some relief to
select patients.
What is the prognosis?
Neuroacanthocytosis is a progressive disease. It is often fatal, generally the result of symptoms that contribute to pneumonia,
cardiomyopathy, eating problems, or other complications. Life expectancy following onset of severe symptoms is typically 5-10
years. However, life span may be near normal for patients with no prominent neurologic or cardiac complications.
What research is being done?
The NINDS supports research on disorders such as neuroacanthocytosis, aimed at increasing scientific understanding of the
disorders and finding ways to prevent and treat them. The molecular changes responsible for some types of neuroacanthocytosis
have recently been identified. Researchers are examining the role of the basal ganglia in neuroacanthocytosis and hope to
correlate the specific genetic abnormalities with the clinical features of the disease. Other research is aimed at identifying
possible causes of sudden death related to heart muscle abnormality in patients with neuroacanthocytosis.
Select this link
to view a list of studies currently seeking patients.
Organizations
WE MOVE (Worldwide Education & Awareness for Movement Disorders)
204 West 84th Street
New York,
NY
10024
wemove@wemove.org
http://www.wemove.org
Tel: 212-875-8312 866-546-3136
Fax: 212-875-8389
|
National Organization for Rare Disorders (NORD)
P.O. Box 1968
(55 Kenosia Avenue)
Danbury,
CT
06813-1968
orphan@rarediseases.org
http://www.rarediseases.org
Tel: 203-744-0100
Voice Mail 800-999-NORD (6673)
Fax: 203-798-2291
|
Office of Rare Diseases
National Institutes of Health, DHHS
6100 Executive Blvd., 3B01, MSC 7518
Bethesda,
MD
20892-7518
http://rarediseases.info.nih.gov
Tel: 301-402-4336
|
National Library of Medicine (NLM)
National Institutes of Health, DHHS
8600 Rockville Pike, Bldg. 38, Rm. 2S10
Bethesda,
MD
20894
http://www.nlm.nih.gov
Tel: 301-496-6308
888-346-3656
|
Prepared by:
Office of Communications and Public Liaison
National Institute of Neurological Disorders and Stroke
National Institutes of Health
Bethesda, MD 20892
NINDS health-related material is provided for information purposes only and does not necessarily represent endorsement by
or an official position of the National Institute of Neurological Disorders and Stroke or any other Federal agency. Advice
on the treatment or care of an individual patient should be obtained through consultation with a physician who has examined
that patient or is familiar with that patient's medical history.
All NINDS-prepared information is in the public domain and may be freely copied. Credit to the NINDS or the NIH is appreciated.
Return to top
Last updated February 14, 2007
